Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

86.61EUR
28 Apr 2017
Change (% chg)

€0.64 (+0.74%)
Prev Close
€85.97
Open
€87.00
Day's High
€88.00
Day's Low
€86.17
Volume
3,454,507
Avg. Vol
2,386,622
52-wk High
€88.00
52-wk Low
€62.50

SASY.PA

Chart for SASY.PA

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €111,902.10
Shares Outstanding(Mil.): 1,292.02
Dividend: 2.96
Yield (%): 3.42

Financials

  SASY.PA Industry Sector
P/E (TTM): 25.56 29.08 30.08
EPS (TTM): 3.39 -- --
ROI: 5.02 13.73 13.25
ROE: 7.60 14.68 14.41

UPDATE 2-Sanofi beats profit forecasts, upbeat on prospects for eczema drug

PARIS, April 28 French drugmaker Sanofi's profit beat forecasts in the first quarter and confirmed its earnings outlook for the year, lifting its shares on Friday.

Apr 28 2017

BRIEF-Regeneron and Sanofi announce Kevzara license application resubmission for review by FDA

* Regeneron and Sanofi announce Kevzara® (sarilumab) Biologics License Application resubmission accepted for review by U.S. FDA

Apr 28 2017

BRIEF-Regeneron says FDA approved for praluent injection

* Regeneron and Sanofi announce FDA approval of a new once-monthly dosing option for Praluent (Alirocumab) injection

Apr 25 2017

BRIEF-Sanofi Genzyme announces positive new six-year data from analysis of lemtrada

* Sanofi genzyme - announced positive new six-year investigational data from post-hoc analysis of extension study of lemtrada (alemtuzumab)

Apr 25 2017

BRIEF-Sanofi and Regeneron announce FDA approval of a once-monthly dosing option for Praluent

* Sanofi and Regeneron announce FDA approval of a new once-monthly dosing option for Praluent (alirocumab) injection

Apr 25 2017

Sanofi files U.S. antitrust lawsuit against Mylan over EpiPen

France's Sanofi SA on Monday sued Mylan NV, accusing the pharmaceutical company of engaging in illegal conduct to squelch competition to its EpiPen allergy treatment, which has been at the center of a public debate over drug prices.

Apr 24 2017

UPDATE 1-Sanofi files U.S. antitrust lawsuit against Mylan over EpiPen

April 24 France's Sanofi SA on Monday sued Mylan NV, accusing the pharmaceutical company of engaging in illegal conduct to squelch competition to its EpiPen allergy treatment, which has been at the center of a public debate over drug prices.

Apr 24 2017

Sanofi files U.S. antitrust lawsuit against Mylan over EpiPen

Sanofi SA on Monday sued Mylan NV, accusing the pharmaceutical company of engaging in illegal conduct to squelch competition to its EpiPen allergy treatment, which has been at the center of a public debate over drug prices.

Apr 24 2017

Sanofi files U.S. antitrust lawsuit against Mylan over EpiPen

April 24 Sanofi SA on Monday sued Mylan NV, accusing the pharmaceutical company of engaging in illegal conduct to squelch competition to its EpiPen allergy treatment, which has been at the center of a public debate over drug prices.

Apr 24 2017

EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis.

Apr 21 2017

More From Around the Web

Earnings vs. Estimates